High incidence of glucose intolerance in Vogt-Koyanagi-Harada disease
- PMID: 10209432
- PMCID: PMC1722769
- DOI: 10.1136/bjo.83.1.39
High incidence of glucose intolerance in Vogt-Koyanagi-Harada disease
Abstract
Aims: To evaluate glucose tolerance of patients with Vogt-Koyanagi-Harada (VKH) disease before systemic corticosteroid therapy, and to assess changes brought on by treatment.
Methods: 20 VKH patients with acute bilateral panuveitis were studied. 20 healthy adults and 11 Behçet's disease patients with active uveoretinitis served as controls. A 75 g oral glucose tolerance test (OGTT) was given in the acute stage of ocular inflammation before systemic corticosteroid therapy. The OGTT was repeated in the convalescent stage of VKH disease in the patients with glucose intolerance before treatment. Insulin response was examined at the same time as the OGTT when possible.
Results: 55% of VKH patients (11/20) showed glucose intolerance but no apparent insulin secretion deficiency was detected. Four of seven patients in the convalescent stage showed improvement of glucose tolerance. None of the normal controls or disease controls showed glucose intolerance.
Conclusion: A high incidence of glucose intolerance was found in the acute stage of VKH disease. However, glucose intolerance improved in most cases after systemic corticosteroid therapy. It is possible that glucose intolerance seen in VKH patients may be related to the autoimmune inflammatory process of this disease.
Figures
Similar articles
-
Acute phase clinical manifestations of patients with Vogt-Koyanagi-Harada disease in Southern China.BMC Ophthalmol. 2023 May 5;23(1):199. doi: 10.1186/s12886-023-02952-y. BMC Ophthalmol. 2023. PMID: 37147563 Free PMC article.
-
Management of ocular complications of Vogt-Koyanagi-Harada syndrome.Int Ophthalmol. 2009 Feb;29(1):33-7. doi: 10.1007/s10792-007-9159-1. Epub 2007 Oct 19. Int Ophthalmol. 2009. PMID: 17952373
-
Outcomes of Vogt-Koyanagi-Harada Disease: A Subanalysis From a Randomized Clinical Trial of Antimetabolite Therapies.Am J Ophthalmol. 2016 Aug;168:279-286. doi: 10.1016/j.ajo.2016.06.004. Epub 2016 Jun 10. Am J Ophthalmol. 2016. PMID: 27296490 Free PMC article. Clinical Trial.
-
[Vogt-Koyanagi-Harada disease].J Fr Ophtalmol. 2017 Jun;40(6):512-519. doi: 10.1016/j.jfo.2017.02.006. Epub 2017 Jun 1. J Fr Ophtalmol. 2017. PMID: 28579215 Review. French.
-
Reappraisal of the management of Vogt-Koyanagi-Harada disease: sunset glow fundus is no more a fatality.Int Ophthalmol. 2017 Dec;37(6):1383-1395. doi: 10.1007/s10792-016-0395-0. Epub 2016 Nov 14. Int Ophthalmol. 2017. PMID: 27844182 Free PMC article. Review.
Cited by
-
Association between advanced glycation end products and uveitis/scleritis activity in patients with active immune-mediated ocular inflammatory diseases.Int Ophthalmol. 2024 Feb 8;44(1):33. doi: 10.1007/s10792-024-02980-7. Int Ophthalmol. 2024. PMID: 38329659 Free PMC article.
-
Decrease in the glyceraldehyde derived advanced glycation end products in the sera of patients with Vogt-Koyanagi-Harada disease.Br J Ophthalmol. 2005 Nov;89(11):1407-9. doi: 10.1136/bjo.2005.072678. Br J Ophthalmol. 2005. PMID: 16234440 Free PMC article.
-
A case of vogt-koyanagi-harada disease associated with polycystic ovary syndrome.J Clin Med Res. 2011 Apr 4;3(2):93-5. doi: 10.4021/jocmr516w. J Clin Med Res. 2011. PMID: 21811536 Free PMC article.
-
Intraocular Inflammation in Diabetic Populations.Curr Diab Rep. 2017 Aug 8;17(10):83. doi: 10.1007/s11892-017-0910-3. Curr Diab Rep. 2017. PMID: 28791537 Review.
-
Association between islet autoantibodies and the prevalence of autoimmune uveitis.Int J Ophthalmol. 2020 Nov 18;13(11):1733-1738. doi: 10.18240/ijo.2020.11.08. eCollection 2020. Int J Ophthalmol. 2020. PMID: 33215003 Free PMC article.
References
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical